Although the American Thoracic Society (ATS) has published standardized guidelines for administering the 6MWT, variability in test administration is widespread. Controlling variability is crucial. Reduced variability translates into more definitive signals thereby decreasing trial sample sizes and costs. Our EQuIP® strategy has been successfully managing endpoint variability for more than a decade.
When using the 6MWT in clinical trials, it is also important to consider the specific requirements of your patient population (e.g., severe functional limitations, need for walking aids or adjunct measures such as supplemental oxygen). CPC has the unique experience and expertise to appropriately customize the conduct of the 6MWT to your patient population while maintaining accuracy and reproducibility.